Standigm Secures $44.5 M in Pre-IPO Funding Round
Summary
The closing marks the last round of funding before Standigm goes to its planned initial public offering (IPO) on the Korea Exchange (KRX) later this year. Standigm and its collaborator, SK holdings C&C opened iCLUE&ASK™, an AI-based drug target identification platform, to the public last September. “Standigm is a highly innovative AI biotech leading the fourth industrial revolution,” Wonho Jeong, Director of SKS PE said. This January, Standigm announced that it repurposed an FDA-approved drug for rheumatoid arthritis and applied for a patent through a partnership with SK Chemicals. Founded in 2015, Standigm has raised total $68 M from leading investors and developed an elite team with multi-disciplinary expertise in pharmacology, chemistry, biology, artificial intelligence, and data structures to ease the pains of patients all over the world.
Funding
Review available funding amount, funding date, investors, and linked company information related to Standigm Secures $44.5 M in Pre-IPO Funding Round in the interactive ISVWorld profile.